Background: Transhiatal and transthoracic oesophagectomy in patients with oesophageal cancer have similar survival rates. Whether these approaches differ in health-related quality of life (HRQoL) is uncertain and was examined in this study. Conclusion: Transhiatal oesophagectomy seems to offer better HRQoL than transthoracic oesophagectomy 6 and 12 months after surgery.
Introduction
The curative treatment of most patients diagnosed with cancer of the oesophagus or the gastro-oesophageal junction includes oesophagectomy 1, 2 , but the optimal surgical approach remains uncertain 3 . The two predominant open surgical approaches for oesophageal cancer are transhiatal and transthoracic oesophagectomy 3 . In the transhiatal approach, oesophagectomy is performed via an abdominal and neck incision 4 . Transthoracic oesophagectomy is performed via an abdominal incision and a thoracotomy (often separate). The anastomosis is usually done in the chest 3 . The transhiatal and transthoracic approaches have similar oncological outcomes 3,5 -8 .
Severe deterioration in health-related quality of life (HRQoL) is a major concern for patients with oesophageal cancer during the first postoperative year and beyond 9, 10 . Co-morbidities and postoperative complications are associated with poor recovery of HRQoL 11, 12 . Therefore, transhiatal oesophagectomy is sometimes preferred in frail patients, for example older people or those with pulmonary co-morbidities 13 . It is less clear whether these two procedures differ regarding postoperative HRQoL. The only study 14 to address this issue suggested a more favourable outcome after transhiatal oesophagectomy up to 3 months after surgery. As a thoracotomy is not performed in the transhiatal approach 4 , it was hypothesized that a transhiatal approach causes less surgical trauma than transthoracic oesophagectomy, and this might reduce pain and pulmonary morbidity 7 resulting in better postoperative HRQoL.
The aim of this study was to test the hypothesis that transhiatal oesophagectomy for cancer is associated with better HRQoL 6 and 12 months after surgery than transthoracic oesophagectomy.
Methods
This was a single-centre prospective cohort study from St Thomas' Hospital in London, UK, between November 2011 and February 2016. The study was started to examine the effects of surgery-related factors on HRQoL in patients with oesophagogastric cancer undergoing surgery. The open transhiatal approach was compared with the open transthoracic approach regarding HRQoL 6 and 12 months after surgery. Informed consent was obtained from all study participants. The study was approved by the National Research Ethics Services in London and West Midlands (11/LO/0335 and 13/WM/0131).
Clinical management
All patients were managed by a well established multidisciplinary upper gastrointestinal cancer team. Study patients had a standard protocol of investigation, including oesophagogastroduodenoscopy and CT. Additional diagnostic measures, such as endoscopic ultrasonography, fluorodeoxyglucose PET or laparoscopy were carried out when indicated clinically. Indications and regimens for neoadjuvant therapy followed established evidence-based standards 15 .
Data collection
The prospectively collected clinical information included: patient and tumour characteristics; surgical details and other treatment variables; predefined complications occurring within 30 days of surgery; and written HRQoL questionnaire responses collected at baseline (before operation), and at 6 and 12 months after surgery. The ASA physical status grade was used to assess the fitness of the patients at the time of surgery. Tumour location and tumour stage were based on pathological examination of the resected tumour specimen according to the seventh edition of the UICC and AJCC Cancer Staging Manual 16 . Postoperative complications were graded according to the Clavien-Dindo classification 17 .
Surgical approach
Decisions on surgical approach for individual patients were made in multidisciplinary meetings. The transhiatal approach was used in older or frail patients with early tumours at the gastro-oesophageal junction. Transhiatal oesophagectomy was undertaken through a laparotomy (without thoracotomy) and a left cervical incision with handsewn anastomosis. Transthoracic oesophagectomy was performed via a right-sided thoracotomy and a laparotomy or a left thoracoabdominal approach with intrathoracic anastomosis. A gastric tube was used as the conduit in all patients. During the study interval, the operations were carried out by one of three high-volume consultant surgeons who applied the same selection criteria for surgical approach. Minimally invasive procedures were also undertaken, but these were not included in the present study.
Health-related quality of life
HRQoL was measured using well established questionnaires, developed and validated by the European Organisation for Research and Treatment of Cancer (EORTC) 18 . The 30-item cancer core questionnaire (EORTC QLQ-C30) has nine multi-item scales, one measuring global quality of life, five measuring functions (physical, role, cognitive, emotional and social functioning) and three measuring symptoms (fatigue, pain and nausea/vomiting), and also six single items measuring symptoms common among patients with cancer in general (dyspnoea, appetite loss, insomnia, constipation, diarrhoea and financial impact) 18 . Oesophageal cancer symptoms were measured using a specific module (EORTC QLQ-OG25) compromising six symptom scales (dysphagia, eating restrictions, reflux, odynophagia, pain and discomfort, and anxiety) and ten single items (eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choking when swallowing, trouble with coughing, trouble talking, weight loss and hair loss) 19 . Each item in both questionnaires has a response on a four-point Likert scale: 'not at all', 'a little', 'quite a bit' and 'very much', except for the items in the global quality-of-life scale, which have seven response alternatives ranging from 'very poor' to 'excellent'. The baseline HRQoL questionnaires were filled in at the time of admission for surgery (approximately 6 weeks after the end of neoadjuvant therapy). These questionnaires were missing for eight patients (5⋅5 per cent). In these patients, questionnaires at time of initiation of neoadjuvant therapy were used because HRQoL after neoadjuvant therapy is known to recover before surgery 20, 21 . Follow-up questionnaires were collected at 6 and 12 months after surgery.
Statistical analysis
Data management and statistical analyses were carried out by a senior biostatistician specialized in HRQoL analyses, who followed the analysis plan decided in a detailed and predefined study protocol. The χ 2 test or Fisher's exact test was used to examine differences in baseline values between the exposure groups. HRQoL questionnaire responses were transformed into scores ranging from 0 to 100. Higher scores correspond to better HRQoL in the function scales and the global quality-of-life scale, whereas higher scores for symptom scales and single items represent more problems. Missing responses were handled as recommended in the EORTC scoring manual 22 . Missing scores for scales and single items, completely missing questionnaires, and absent clinical data were assumed to be missing at random and dealt with using complete-case analysis. Mean scores for each surgical procedure were calculated with 95 per cent confidence intervals. Linear mixed-effects models were used to calculate mean score differences (MSDs) with 95 per cent confidence intervals between the two surgical approach groups. In all analyses, adjustments for potential confounding factors were made using all of the following a priori selected co-variables that could influence both the surgical approach and HRQoL outcomes: baseline value for each HRQoL scale or individual item (continuous variable), age (continuous variable), ASA grade (I-II or III-IV), tumour location (oesophagus or gastro-oesophageal junction), tumour stage (0-II or III), neoadjuvant chemotherapy (yes or no), adjuvant therapy started (yes or no) and complications (none, Clavien-Dindo I-II or III-IV). Statistical significance was tested using the Student's t test only when the MSD between groups was at least 10, because such differences are considered clinically relevant and noticeable among patients according to previous studies, and such restrictive significance testing reduces the risk of chance errors 23, 24 .
A power calculation showed that, for more than 80 per cent power to detect a significant two-tailed P value (< 0⋅050) for a clinically relevant difference of MSD 10 with a standard deviation of 11, a sample size of at least 20 participants in each group would be required. The reference category in all statistical analyses was the transhiatal group. The statistical software SAS ® version 9.4 (SAS Institute, Cary, North Carolina, USA) was used for all analyses.
Results
Some 228 of 251 patients underwent open transhiatal or transthoracic oesophagectomy for cancer of the lower third of the oesophagus or gastro-oesophageal junction.
Of these, 146 patients (64⋅0 per cent) responded to the baseline and follow-up HRQoL questionnaires until death or for at least 6 months at study termination, and were included in this study. Eighty-six patients (58⋅9 per cent) underwent transhiatal and 60 (41⋅1 per cent) transthoracic oesophagectomy.
At 6 months, five patients (3⋅4 per cent) had died, 21 (14⋅4 per cent) were too ill to answer the questionnaires (9 in the transhiatal and 12 in the transthoracic group), questionnaires were missing for two (1⋅4 per cent) owing to an administrative error, and seven (4⋅8 per cent) were non-responders for other reasons. Hence, data from 111 of 141 surviving patients (78⋅7 per cent) were analysed. At 12 months, 123 patients were potentially eligible for the HRQoL assessment. Some 20 patients (16⋅3 per cent) had died, 22 (17⋅9 per cent) were too ill to answer the questionnaires (11 in the transhiatal and 11 in the transthoracic group) and seven (5⋅7 per cent) were non-responders for other reasons. Hence, 74 of 103 surviving patients (71⋅8 per cent) were included in the analysis.
Non-participation rates among the surviving patients were 17 per cent for transhiatal and 28 per cent for transthoracic oesophagectomy groups at 6 months, and 25 and 33 per cent respectively at 12 months. Comparison between responders and non-responders showed that there were no statistically significant differences between the two groups at 6 months (Table S1, supporting information) At 12 months, the non-responder group included more young patients and fewer women than the group of responders (Table S2 , supporting information).
Characteristics of the study patients are presented in Table 1 . Details of the neoadjuvant regimen were available for 119 of the 128 patients who underwent neoadjuvant therapy (93⋅0 per cent). Of these, 115 (96⋅6 per cent) had a platinum-based triple therapy and four (3⋅4 per cent) had capecitabine with or without platinum-based agents or antibodies. Patients in the transhiatal oesophagectomy group were older, had more early-stage tumours and less often underwent neoadjuvant chemotherapy than those in the transthoracic group. There was no major difference in the occurrence of postoperative complications ( Table 1) .
Health-related quality of life 6 months after surgery
Adjusted mean HRQoL scores from the general cancer questionnaire (QLQ-C30) at 6 months after surgery are shown in Fig. 1 and Table S3 (supporting information). Compared with transhiatal oesophagectomy, transthoracic oesophagectomy was associated with worse role function (MSD -12, 95 per cent c.i. -23 to 0); this difference was statistically significant (P = 0⋅046). As regards oesophageal cancer-specific items, patients had more weight loss concerns after transthoracic oesophagectomy compared with patients after transhiatal surgery (MSD 14, 0 to 27), but this difference was not statistically significant (P = 0⋅051) ( Fig. 1; Table S4 , supporting information).
Health-related quality of life 12 months after surgery
At 12 months, role function (MSD -10, 95 per cent c.i. -23 to 3) was still worse in the transthoracic group, but this difference was not statistically significant (P = 0⋅121) ( Fig. 1; Table S5 , supporting information). Patients had worse nausea and vomiting (MSD 11, 0 to 22, P = 0⋅045), dyspnoea (MSD 13, 1 to 25; P = 0⋅029) and constipation (MSD 20, 7 to 33; P = 0⋅003) after transthoracic oesophagectomy than after transhiatal surgery. The transthoracic group experienced less clinically relevant oesophageal pain and discomfort (MSD -10, 95 per cent c.i. -22 to 1) compared with the transhiatal group, but the difference between the groups was not statistically significant (P = 0⋅081) ( Fig. 1; Table S6 , supporting information).
Discussion
The results of this study suggest that transhiatal oesophagectomy is associated with better HRQoL 6 and 12 months after surgery than transthoracic oesophagectomy. Role function at 6 months, and nausea and vomiting, dyspnoea and constipation at 12 months, were statistically significantly worse in the transthoracic group.
The strengths of this study included its longitudinal design with detailed clinical information, the use of validated HRQoL questionnaires, and inclusion of patients who underwent a transhiatal or transthoracic procedure. Surgical trials are prone to bias because of the individual surgeon's experience. This was minimized here by studying three high-volume surgeons with similar experience in both surgical techniques. A weakness is the limited sample size, which meant that some clinically relevant differences were not statistically significant despite the power calculation showing adequate statistical power for both time points. A higher proportion of patients in the transthoracic group did not answer the HRQoL questionnaires because they were too ill, possibly introducing bias in favour of the transthoracic approach as these patients would probably have scored worst in the HRQoL assessments. Non-participation and loss to follow-up for other reasons could have introduced selection bias. However, it is unlikely that these factors were associated with the surgical approach. There were no differences at 6 months, and only minor differences in age-and sex-distribution at 12 months, between responders and non-responders. Thus, any selection bias is likely to be random, or in favour of the transthoracic group. Bias by confounding was mitigated by adjusting for several potential confounding factors in the analyses.
One earlier study comparing HRQoL after transthoracic and transhiatal oesophagectomy was a Dutch RCT 14 . Outcomes were similar to those of the present study. Transhiatal oesophagectomy was associated with fewer physical symptoms and better activity levels than transthoracic oesophagectomy up to 3 months after surgery. Most HRQoL outcomes, such as physical, role and social functioning, as well as pain and mental health scores, slightly favoured transhiatal oesophagectomy in the Dutch study up to 18 months after surgery. However, the differences between the groups were not statistically significant 14 . It is also important to examine this research question in cohort studies. Inclusion criteria for cohort studies typically mirror clinical practice better. Randomized trials often have strict inclusion criteria, which might exclude patients who have the worst HRQoL after surgery 25 . It is important to note that neoadjuvant therapy was not used during the Dutch trial 14 , which may have affected postoperative HRQoL 20, 21, 26, 27 .
The present results suggest that several HRQoL measures are better after transhiatal compared with transthoracic oesophagectomy. It is important to note that most scales and items favoured the transhiatal approach, even though the MSDs were often between 5 and 10, and therefore of less clinical relevance. Some of the differences could be related to the thoracotomy, higher rates of respiratory complications and the greater sequelae of certain complications, including anastomotic leak, in the transthoracic group. The anastomosis after transhiatal oesophagectomy is located in the neck, and a leak here may have less severe consequences. The better scores for nausea and vomiting, and constipation may reflect fewer gastric emptying-related and functional gastrointestinal problems after transhiatal oesophagectomy. It would be of value to validate the present results in studies with a larger sample size, longer follow-up and from more individual centres. It would also be interesting to compare HRQoL outcomes between minimally invasive transhiatal or transthoracic approaches, and open transhiatal oesophagectomy. Although decisions regarding the optimal surgical approach in open oesophagectomy must be taken on an individual basis and include consideration of various oncological factors and surgeon experience, the present results lean towards transhiatal oesophagectomy.
